Novel hybrids of natural isochroman-4-one bearing N-substituted isopropanolamine as potential antihypertensive candidates

Bioorg Med Chem. 2013 May 1;21(9):2495-502. doi: 10.1016/j.bmc.2013.02.044. Epub 2013 Mar 14.

Abstract

A series of novel hybrids of natural isochroman-4-one bearing isopropanolamine moiety were designed, synthesized and evaluated for their antihypertensive activity. It was found that compound IIId, prepared by hybridizing N-isopropyl substituted isopropanolamine functionality to a phenolic oxygen of isochroman-4-one, exhibited potent β(1)-adrenoceptor blocking effect comparable to the well-known antihypertensive drug propranolol. Additionally, IIId significantly reduced the systolic and diastolic blood pressure in SHRs by over 40%, which was obviously stronger than the lead compounds 7,8-dihydroxy-3-methyl-isochroman-4-one (XJP) and its analogue XJP-B. Overall, IIId may be a promising antihypertensive candidate for further investigation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / chemical synthesis
  • Adrenergic beta-Antagonists / chemistry
  • Adrenergic beta-Antagonists / pharmacology*
  • Animals
  • Antihypertensive Agents / chemical synthesis
  • Antihypertensive Agents / chemistry
  • Antihypertensive Agents / pharmacology*
  • Blood Pressure / drug effects
  • Chromones / chemistry*
  • Dose-Response Relationship, Drug
  • Hypertension / drug therapy*
  • Male
  • Propanolamines / chemical synthesis
  • Propanolamines / chemistry
  • Propanolamines / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Adrenergic, beta / metabolism
  • Structure-Activity Relationship

Substances

  • Adrenergic beta-Antagonists
  • Antihypertensive Agents
  • Chromones
  • Propanolamines
  • Receptors, Adrenergic, beta
  • monoisopropanolamine